ATE409749T1 - Verfahren zur reinigung von alphaviralen replikon partikeln - Google Patents

Verfahren zur reinigung von alphaviralen replikon partikeln

Info

Publication number
ATE409749T1
ATE409749T1 AT01941874T AT01941874T ATE409749T1 AT E409749 T1 ATE409749 T1 AT E409749T1 AT 01941874 T AT01941874 T AT 01941874T AT 01941874 T AT01941874 T AT 01941874T AT E409749 T1 ATE409749 T1 AT E409749T1
Authority
AT
Austria
Prior art keywords
methods
purifying
replicon particles
purification
disclosed
Prior art date
Application number
AT01941874T
Other languages
English (en)
Inventor
John Polo
Catherine Greer
Maria Calderon-Cacia
La Vega Daniel Del
Thomas Dubensky
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE409749T1 publication Critical patent/ATE409749T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701Specific hybridization probes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/36011Togaviridae
    • C12N2770/36111Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36151Methods of production or purification of viral material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Powder Metallurgy (AREA)
  • Disintegrating Or Milling (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
AT01941874T 2000-05-31 2001-05-31 Verfahren zur reinigung von alphaviralen replikon partikeln ATE409749T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20837600P 2000-05-31 2000-05-31

Publications (1)

Publication Number Publication Date
ATE409749T1 true ATE409749T1 (de) 2008-10-15

Family

ID=22774372

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01941874T ATE409749T1 (de) 2000-05-31 2001-05-31 Verfahren zur reinigung von alphaviralen replikon partikeln

Country Status (9)

Country Link
US (4) US6767699B2 (de)
EP (1) EP1285080B1 (de)
AT (1) ATE409749T1 (de)
AU (1) AU2001275191A1 (de)
CA (1) CA2410948C (de)
DE (1) DE60135983D1 (de)
DK (1) DK1285080T3 (de)
ES (1) ES2312447T3 (de)
WO (1) WO2001092552A2 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
ES2624854T3 (es) 2001-05-31 2017-07-17 Glaxosmithkline Biologicals Sa Partículas de replicón de alfavirus quimérico
ES2330202T5 (es) * 2001-09-06 2014-01-20 Alphavax, Inc. Sistemas vectores basados en replicones de alfavirus
US7195905B2 (en) * 2001-12-10 2007-03-27 Baxter Healthcare S.A. Enveloped virus vaccine and method for production
MXPA04010603A (es) 2002-04-30 2004-12-13 Oncolytics Biotech Inc Metodos mejorados de purificacion viral.
WO2004030631A2 (en) 2002-10-01 2004-04-15 Chiron Corporation Anti-cancer and anti-infectious disease compositions and methods for using same
CA2509973C (en) * 2002-12-13 2013-02-26 Alphavax, Inc. Multi-antigenic alphavirus replicon particles and methods
DK3246399T3 (da) * 2002-12-13 2021-10-04 Alphavax Inc Alfavirus-partikler og fremgangsmåder til fremstilling
MXPA05010007A (es) * 2003-03-20 2006-03-10 Alphavax Inc Replicones de alfavirus y construcciones auxiliares mejorados.
PT1651666E (pt) * 2003-07-11 2009-08-28 Alphavax Inc Vacinas de citomegalovírus à base de alfavírus
MXPA06013124A (es) 2004-05-18 2007-05-23 Alphavax Inc Vectores de alfavirus derivados de tc-83, particulas y metodos.
US20090104226A1 (en) 2004-05-21 2009-04-23 Novartis Vaccines And Diagnostics Inc. Alphavirus Vectors for Respiratory Pathogen Vaccines
US7901921B2 (en) * 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
EP1736538A1 (de) * 2005-06-21 2006-12-27 Cytos Biotechnology AG Prozess für die preparative Reinigung von Virus-ähnlichen Partikeln (VLPs)
KR100760525B1 (ko) * 2006-04-13 2007-10-04 김재만 병원성 미생물의 무증폭 다중 정량 검출킷트 및 검출방법
US20090022760A1 (en) * 2006-09-12 2009-01-22 Alphavax Alphavirus Replicon Particles Matched to Protein Antigens as Immunological Adjuvants
ES2746960T3 (es) 2006-09-12 2020-03-09 Alphavax Inc Partículas de replicón de alfavirus que codifican IL-12 como adyuvantes inmunológicos
US20090047255A1 (en) * 2006-11-03 2009-02-19 Alphavax, Inc. Alphavirus and Alphavirus Replicon Particle Formulations and Methods
WO2008156829A2 (en) * 2007-06-21 2008-12-24 Alphavax, Inc. Promoterless cassettes for expression of alphavirus structural proteins
ES2525707T3 (es) 2008-12-01 2014-12-29 Alphavax, Inc. Uso de microRNAs para el control de ácidos nucleicos colaboradores de virus
CN105056229A (zh) 2009-01-05 2015-11-18 埃皮托吉尼西斯股份有限公司 佐剂组合物及使用方法
US10072307B1 (en) 2009-01-23 2018-09-11 Colorado State University Research Foundation Isolation of viruses using anionic resin beads
ES2540958T3 (es) 2009-04-08 2015-07-15 Alphavax, Inc. Partículas de replicón de alfavirus que expresan TRP2
EP2598223B1 (de) 2010-07-30 2022-04-06 EMD Millipore Corporation Chromatographiemedien und verfahren
EP2625264B1 (de) 2010-10-08 2022-12-07 Terumo BCT, Inc. Verfahren und systeme für züchtung und ernte von zellen in einem hohlfaser-bioreaktorsystem mit steuerungsbedingungen
BR112013032410A2 (pt) 2011-06-24 2017-01-17 Epitogenesis Inc composições farmacêuticas compreendendo uma combinação de veículos, vitaminas, taninos e flavonoides de seleção como imunomoduladores específicos de antígeno
EP3068866B1 (de) 2013-11-16 2018-04-25 Terumo BCT, Inc. Zellenexpansion in einem bioreaktor
JP6783143B2 (ja) 2014-03-25 2020-11-11 テルモ ビーシーティー、インコーポレーテッド 培地の受動的補充
CN106794389A (zh) 2014-09-02 2017-05-31 Emd密理博公司 具有纳米原纤化表面特征的高表面积纤维介质
CN106715676A (zh) 2014-09-26 2017-05-24 泰尔茂比司特公司 按计划供养
CN107001410A (zh) 2014-12-08 2017-08-01 Emd密理博公司 混合床离子交换吸附剂
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
CA3009278A1 (en) 2015-12-23 2017-06-29 Valneva Austria Gmbh Zika virus vaccine
CN109415696A (zh) 2016-05-25 2019-03-01 泰尔茂比司特公司 细胞扩增
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
US11702634B2 (en) 2017-03-31 2023-07-18 Terumo Bct, Inc. Expanding cells in a bioreactor
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
EP3684404A1 (de) 2017-09-21 2020-07-29 Valneva SE Verfahren zur herstellung von pharmazeutischen zusammensetzungen mit immunogenem chikungunya-virus chikv-delta5nsp3
NL2022538B1 (en) 2019-02-08 2020-08-19 Academisch Ziekenhuis Groningen Methods for providing purified viral particles of Semliki Forest Virus (SFV), preparations obtainable thereby, and uses thereof.
US12043823B2 (en) 2021-03-23 2024-07-23 Terumo Bct, Inc. Cell capture and expansion
US12209689B2 (en) 2022-02-28 2025-01-28 Terumo Kabushiki Kaisha Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device
AU2024208643A1 (en) 2023-01-12 2025-06-26 Bavarian Nordic A/S RECOMBINANT MODIFIED saRNA (VRP) FOR CANCER VACCINE
WO2024163370A1 (en) * 2023-01-30 2024-08-08 Thermo Finnigan Llc Separation of long oligonucleotides

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466788A (en) * 1985-03-07 1995-11-14 Mycogen Plant Science, Inc. Subgenomic promoter
ES8800988A1 (es) 1985-04-05 1987-12-16 Meloy Lab Procedimiento de producir interferona humana.
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
WO1988000472A1 (en) 1986-07-23 1988-01-28 Aphton Corporation Immunogens and improved methods of making immunogens
US5716826A (en) 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US5093239A (en) 1988-05-02 1992-03-03 Eastman Kodak Company Reagents for detecting oxidase positive microorganisms
US5614404A (en) 1988-06-10 1997-03-25 Theriod Biologics, Incorporated Self-assembled, defective, non-self-propagating lentivirus particles
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5026686A (en) 1989-02-01 1991-06-25 Washington University Antiviral peptides
US5185440A (en) 1989-06-20 1993-02-09 North Carolina State University cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof
EP0845537A1 (de) 1989-08-18 1998-06-03 Chiron Corporation Rekombinante Retroviren, die einen Prodrug exprimieren, zur Behandlung von GVhD
CA2094608A1 (en) 1990-10-22 1992-04-23 John D. Taylor Dna construct for providing rna therapy
SE9003978D0 (sv) 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
US5279823A (en) 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE
WO1994017813A1 (en) 1993-02-08 1994-08-18 Paravax, Inc. Defective sindbis virus vectors that express toxoplasma gondii p30 antigens
DE4315109A1 (de) 1993-05-06 1994-11-10 Inst Pflanzengenetik & Kultur Verfahren und Vektorkonstrukt zur Expressionssteigerung von Transgenen
EP0647716B1 (de) 1993-07-06 2003-09-24 Universite De Nice-Sophia Antipolis Vektor, enthält ein bei ARN-Polymerase-III transcriptes Virus-Gen
US5837503A (en) 1993-07-07 1998-11-17 Universite De Nice-Sophia-Antipolis Vector containing viral gene transcribed by RNA polymerase III and methods for use
WO1995007994A2 (en) 1993-09-15 1995-03-23 Viagene, Inc. Recombinant alphavirus vectors
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5591579A (en) 1993-12-21 1997-01-07 Washington University Indicator cell line for detecting RNA viruses and method therefor
IL112371A0 (en) 1994-01-25 1995-03-30 Res Dev Foundation A novel protein from aedes albopictus cells and methods for its use
US5498537A (en) * 1994-03-09 1996-03-12 Cellco, Inc. Serum-free production of packaged viral vector
US5532154A (en) 1994-03-21 1996-07-02 Research Development Foundation Mutated alpha virus
SE9401091D0 (sv) 1994-03-31 1994-03-31 Bioption Ab Alphavirus cDNA vectors
GB9406498D0 (en) 1994-03-31 1994-05-25 Smithkline Beecham Biolog Novel compounds
SE9401709D0 (sv) 1994-05-18 1994-05-18 Mathilda Sjoeberg Improved alphavirus vectors for expression of heterologous DNA
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5837520A (en) * 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US5797870A (en) 1995-06-07 1998-08-25 Indiana University Foundation Pericardial delivery of therapeutic and diagnostic agents
EP0847442A1 (de) 1995-08-30 1998-06-17 Genzyme Corporation Chromatographische reinigung von adenoviren und aav
WO1997016169A1 (en) 1995-11-01 1997-05-09 Chiron Corporation Treatment of a cardiovascular indication by delivery of therapeutics to the pericardial space
WO1997024447A1 (en) 1996-01-02 1997-07-10 Chiron Corporation Immunostimulation mediated by gene-modified dendritic cells
AU2051297A (en) 1996-02-15 1997-09-02 Chiron Corporation Gene therapy method using fgf-5
WO1997038087A2 (en) 1996-04-05 1997-10-16 Chiron Corporation Alphaviral vector with reduced inhibition of cellular macromolecular synthesis
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
AU3210997A (en) 1996-05-24 1997-12-09 University Of Maryland At Baltimore Dna vaccines for eliciting a mucosal immune response
US5843712A (en) 1996-06-06 1998-12-01 The Trustees Of Columbia University In The City Of New York Sindbis virus expression system for recombinant antibody production
WO1998013511A1 (en) 1996-09-25 1998-04-02 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Retroviral packaging cassettes amplified in the cytoplasm by autocatalytic togavirus vectors
CA2268353A1 (en) 1996-10-10 1998-04-16 Henrik Garoff Alphavirus-retrovirus vectors
WO1998026084A1 (en) 1996-12-09 1998-06-18 Wolfgang Andreas Renner Expression of active interferon beta 1 using recombinant rna replicons
US6261823B1 (en) * 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
US5811407A (en) 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US6261570B1 (en) 1997-05-20 2001-07-17 The United States Of America As Represented By The Secretary Of The Army Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants
AU8847798A (en) 1997-08-15 1999-03-08 Inex Pharmaceuticals Corporation Semliki forest virus vectors for gene transfer into non-endothelial cardiovascular cells
US6060308A (en) 1997-09-04 2000-05-09 Connaught Laboratories Limited RNA respiratory syncytial virus vaccines
JP2001517433A (ja) 1997-09-24 2001-10-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 非霊長類レンチウイルスベクターおよびパッケージングシステム
ES2268797T3 (es) 1997-11-14 2007-03-16 Sanofi Pasteur Limited Vectores alvirus.
BR9815285A (pt) 1997-11-14 2001-11-13 Connaught Lab Vetores alfavìrus para vacina de paramixovìrus
CA2309765A1 (en) 1997-12-18 1999-06-24 G.D. Searle & Co. Venezuelan equine encephalitis virus vectors expressing tumor-associated antigens to induce cancer immunity

Also Published As

Publication number Publication date
US20100055128A1 (en) 2010-03-04
EP1285080B1 (de) 2008-10-01
DK1285080T3 (da) 2008-12-01
US20120231526A1 (en) 2012-09-13
CA2410948A1 (en) 2001-12-06
CA2410948C (en) 2012-07-17
EP1285080A2 (de) 2003-02-26
AU2001275191A1 (en) 2001-12-11
US20050112752A1 (en) 2005-05-26
WO2001092552A2 (en) 2001-12-06
US20020015945A1 (en) 2002-02-07
US6767699B2 (en) 2004-07-27
ES2312447T3 (es) 2009-03-01
DE60135983D1 (de) 2008-11-13
WO2001092552A3 (en) 2002-05-23

Similar Documents

Publication Publication Date Title
ATE409749T1 (de) Verfahren zur reinigung von alphaviralen replikon partikeln
ATE472335T1 (de) Chimere alphavirus-replikon-partikel
ATE420965T1 (de) Von tc-83 abgeleitete alphavirus-vektoren, partikel und verfahren
FI932678A0 (fi) Pao alfavirus baserande DNA expressionssystem
DE69942280D1 (de) Zusammensetzungen und verfahren zur verpackung von alpavirus-vektoren
WO2005035556A3 (en) Sars-coronavirus virus-like particles and methods of use
DE60129695D1 (de) Steigerung von durch antikörper-zytokin-fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme
EA202190907A1 (ru) Репликоны на основе альфавируса для введения биотерапевтических средств
NO964862D0 (no) Papillomavirusvaksiner
ATE384785T1 (de) Herstellung von viren, virusisolaten, und impfstoffen
RU2019107976A (ru) Композиция вакцины
MX2022014161A (es) Vacunas contra sars-cov-2.
DK1519944T3 (da) Fremgangsmåder til fremstilling af fibrinogen
ATE302268T1 (de) Methode zur gewinnung und reinigung von poxviren aus infizierten zellen
WO2004000220A3 (en) Methods for purifying viral particles for gene therapy
WO2003072725A3 (en) Recombinant negative strand virus rna expression systems and vaccines
PH12018502197A1 (en) Improved method for producing virus like particles
WO2005011571A3 (en) Hepatitis virus core proteins as vaccine platforms and methods of use thereof
WO2008027560A3 (en) Holin-enhanced vaccines and reagents, and methods of use thereof
MXPA02012593A (es) Particulas de tipo virus del virus de la diarrea viral bovina.
DE60231821D1 (de) Rekombinante tollwut-vakzine und verfahren zu ihrer herstellung und verwendung
DE60040219D1 (de) Infektiöses cdna klon des gb-virus b und dessen verwendungen
DE50212580D1 (de) Rekombinantes mva mit der fähigkeit zur expression von hcv struktur-antigenen
ATE381351T1 (de) Anwendung des herpes simplex virus glykoproteins- d zur unterdrückung von immunantworten
DK1165797T3 (da) Partikler til genterapi

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1285080

Country of ref document: EP